Silverback Therapeutics, Inc. announced Thilo Schroeder, Ph.D. will not stand for re-election as a member of the company's board of directors when his term as a class II director expires at the company's 2022 annual meeting of stockholders and on March 14, 2022, Dr. Schroeder resigned as a member of the audit committee of the board of directors of the company to focus on other endeavors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.88 USD | -1.11% | -1.99% | +62.04% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.04% | 870M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- SPRY Stock
- News ARS Pharmaceuticals, Inc.
- Silverback Therapeutics, Inc. Announces Thilo Schroeder Will Not Stand for Re-Election as Member of the Company Board of Directors